Serviam_I_Will_Serve
304 posts











Communism is merely Talmudic Judaism transposed onto a hapless society; an Halachic heaven for the chosen, a Godless prison-system for the cattle...

Henry Nowak bled to death while in handcuffs. Meanwhile, his foreign murderer was treated as the victim. England has committed the greatest act of betrayal of its own people. This is why young white men are questioning everything, including WWII narratives.


Henry Nowak bled to death while in handcuffs. Meanwhile, his foreign murderer was treated as the victim. England has committed the greatest act of betrayal of its own people. This is why young white men are questioning everything, including WWII narratives.





VIDEO | "[Israel] should counterattack every single hour of every single day, and no institution should be spared." World Jewish Congress President Ron Lauder has called for deploying Israel’s national intelligence agency, the Mossad, against Israel’s adversaries in the global public relations arena. Lauder made the remarks during his address at the Jerusalem Post conference in New York City this week, advocating for a clandestine approach to countering anti-Israel narratives. To spearhead this media offensive, Lauder proposed recruiting a specialized brigade of 'young and attractive' Israelis to dominate global media platforms. The billionaire stated that Israel needs these individuals to be on screens every single hour of every day, working overtime to make the case for the state. He framed the initiative as a strategic advantage, asserting that "while the Arabs may have oil," Israel has an abundance of smart, handsome, young men and women who can work on propaganda in order to counteract the rising tide of anti-Israel sentiment in light of the genocide in Gaza.




Why did Catholic, Michael Knowles join a Jewish club at Yale?


The demon of Fatima: ‘You should definitely pray to me, and also these other demons.’ Galatians 1:8–9 (ESV): »But even if we or an angel from heaven should preach to you a gospel contrary to the one we preached to you, let him be accursed. As we have said before, so now I say again: If anyone is preaching to you a gospel contrary to the one you received, let him be accursed.«





BREAKING: Largest Human Cancer Study of Ivermectin + Mebendazole Is Now PEER-REVIEWED and PUBLISHED in a MAJOR Cancer Journal 84.4% of cancer patients taking ivermectin + mebendazole for 6 months declared either CANCER DISAPPEARANCE, TUMOR REGRESSION, or CANCER STABILIZATION. Our study, “Real-world Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort,” is now peer-reviewed and published in Anticancer Research—a major international oncology journal of the International Institute of Anticancer Research (IIAR), established in 1995. The results represent one of the most compelling clinical signals ever documented for repurposed anti-parasitic therapies in oncology. A diverse population of cancer patients (n=197) was prescribed compounded ivermectin–mebendazole through a U.S. telemedicine platform, with each capsule containing 25 mg ivermectin and 250 mg mebendazole. Participants were followed for approximately six months using standardized digital surveys assessing cancer outcomes, medication adherence, and tolerability. At approximately six months post-treatment initiation, we observed an 84.4% Clinical Benefit Ratio (CBR)—meaning more than four out of five patients reported either: No evidence of disease (32.8%) Tumor regression (15.6%) or Cancer stabilization (36.1%) Importantly, adherence was remarkably high, with 86.9% completing the initial prescription and 66.4% remaining on therapy at six months. Side effects were predominantly mild and manageable, reported in 25.4% of patients (primarily gastrointestinal), with 93.6% of those experiencing side effects continuing treatment after minor dosing adjustments. This groundbreaking peer-reviewed publication was made possible through a unique collaboration between The Wellness Company, the McCullough Foundation, and the Chairman of the President’s Cancer Panel—uniting real-world clinical data, frontline medical experience, and epidemiologic expertise to evaluate inexpensive, repurposed therapies with major translational potential. With these extraordinarily promising results, double-blind, placebo-controlled clinical trials are now required. In the meantime, many cancer patients are exercising their right to try. @twc_health @McCulloughFund @IIAR_Journals @P_McCulloughMD @DrHarveyRisch @DrKellyVictory @jathorpmfm @drdrew @PeterGillooly @FosterCoulson




